NSE · NEPHROPLUS · Healthcare
Nephrocare Health Serv Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1,023 Cr with net profit ₹77 Cr — a 7.51% net margin, versus 6.63% the period before.
Shareholding
As of 2026-06-30
- Promoter63.85%
- Public18.32%
- FII8.78%
- DII9.05%
44,091 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.73× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #19 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,29,234 Cr | 244.11 | 13.63 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,09,470 Cr | 73.81 | 10.19 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,634 Cr | 269.56 | 7.24 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,513 Cr | 50.7 | 9.37 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,038 Cr | 298.29 | 9.19 | 8.48% | 8.36% |
| Global Health Limited | ₹38,082 Cr | 264.25 | 9.61 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,895 Cr | 136.55 | 9.04 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,496 Cr | 239.03 | 12.55 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹16,888 Cr | 51.6 | 5.44 | 10.37% | 17.18% |
| Rainbow Childrens Medicare Ltd. | ₹15,420 Cr | 62.33 | 9.24 | 16.89% | 16.34% |
| Nephrocare Health Serv Limited(this company) | ₹6,869 Cr | 91.69 | 6.15 | 6.88% | 7.69% |
AI analysis
AI-generated · google/gemini-2.5-flashNephrocare Health Serv Limited (NEPHROPLUS) has a market capitalization of Rs 6393 Cr. The company reported a revenue of Rs 769.92 Cr and an EPS of Rs 380.15. The debt-to-equity ratio stands at 0.53.
Positives
- +The Return on Equity (ROE) of 12% indicates efficient use of shareholder funds.
- +The Return on Capital Employed (ROCE) of 13.18% shows effective utilization of capital.
- +The debt-to-equity ratio of 0.53 suggests a manageable level of debt.
- +Promoter holding of 63.8547% as of June 30, 2026 indicates significant insider commitment.
Negatives
- −The trailing twelve-month P/E ratio is 0, which may indicate that the company is not currently generating profits or that the EPS figure provided is not fully representative.
- −The net profit for the quarter ending September 2025 was negative at Rs -9.47 Cr, indicating a loss in that period.
- −The promoter holding decreased from 79.055% in July 2025 to 63.8547% by June 2026, a reduction of 15.2003 percentage points.
- −The quarterly EPS figures are not available in the provided data.
Financial Performance
For the fiscal year ending March 2025, Nephrocare Health Serv Limited reported a revenue of Rs 769.915 Cr and a net profit of Rs 67.096 Cr. The company's earnings per share (EPS) for this period was Rs 8.01. Quarterly results show revenue of Rs 265.62 Cr and net profit of Rs 30.37 Cr for the quarter ending March 2026.
Profitability & Returns
The company achieved a Return on Equity (ROE) of 12% and a Return on Capital Employed (ROCE) of 13.18%. The EPS was Rs 380.15. The latest annual net profit was Rs 67.096 Cr for the period ending Mar 2025.
Balance Sheet
Nephrocare Health Serv Limited has a book value per share of Rs 3288.65. The company's debt-to-equity ratio is 0.53, indicating its reliance on debt financing relative to equity. The market capitalization is Rs 6393 Cr.
Ownership & Pledges
As of June 30, 2026, promoter holding in Nephrocare Health Serv Limited was 63.8547%. Foreign Institutional Investors (FIIs) held 8.7838% and Domestic Institutional Investors (DIIs) held 9.0454%. Public shareholding was 18.3161%. There are no reported promoter pledges.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Nephrocare Health Serv Limitedshare price & fundamentals